{'fraction_non_alphanumeric': 0.01618578465869106, 'fraction_numerical': 0.0063335679099225895, 'mean_word_length': 5.292035398230088, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Noninvasive Continuous Blood Glucose Monitoring by Dielectric Spectroscopy

The Alertgy noninvasive continuous blood glucose monitor (NICBGM) is a novel wristband device that reports glucose levels without any entailing skin puncture. This study evaluated the performance of this device compared with an FDA-approved glucose meter in patients with type 2 diabetes. Methods: The Alertgy DeepGluco NICBGM device measures changes in the dielectric spectrum it collects specific to blood glucose levels three times a minute. This spectral data is analyzed by using neural network analysis, machine learning and then with a calibration process is used to generate algorithms to estimate blood glucose (BG) values once the system is calibrated to the individual. The Roche Accuchek Inform II glucometer was used as a reference technique for calibration and then to determine the accuracy of blood glucose determinations. 27 patients completed three or more 120-minute sessions. Mean absolute relative difference (MARD) was calculated on the data collected. Results: MARD values were compiled for two or more days of data collection following the first day of calibration. The MARD for all measurements was found to be 15.3. Conclusions: The resultant MARD suggest that this technique can achieve equivalent performance to that of existing CGM devices presently approved by the FDA when the same reference technique is utilized.